DK2885639T3 - COMPLEX SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND THEIR APPLICATION - Google Patents

COMPLEX SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND THEIR APPLICATION

Info

Publication number
DK2885639T3
DK2885639T3 DK13752873.3T DK13752873T DK2885639T3 DK 2885639 T3 DK2885639 T3 DK 2885639T3 DK 13752873 T DK13752873 T DK 13752873T DK 2885639 T3 DK2885639 T3 DK 2885639T3
Authority
DK
Denmark
Prior art keywords
application
antibody fragments
specific antibodies
complex specific
complex
Prior art date
Application number
DK13752873.3T
Other languages
Danish (da)
Inventor
Christian Frisch
Achim Knappik
Stefan Härtle
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Application granted granted Critical
Publication of DK2885639T3 publication Critical patent/DK2885639T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format
    • G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK13752873.3T 2012-08-17 2013-08-08 COMPLEX SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND THEIR APPLICATION DK2885639T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12180835 2012-08-17
US201261684836P 2012-08-20 2012-08-20
PCT/EP2013/066625 WO2014026905A1 (en) 2012-08-17 2013-08-08 Complex-specific antibodies and antibody fragments and its use

Publications (1)

Publication Number Publication Date
DK2885639T3 true DK2885639T3 (en) 2019-07-08

Family

ID=50101254

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13752873.3T DK2885639T3 (en) 2012-08-17 2013-08-08 COMPLEX SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND THEIR APPLICATION

Country Status (10)

Country Link
US (4) US20150197579A1 (en)
EP (2) EP3540438A1 (en)
JP (1) JP6437913B2 (en)
KR (1) KR102410763B1 (en)
CN (1) CN104995517B (en)
AU (1) AU2013304237B2 (en)
CA (1) CA2878814C (en)
DK (1) DK2885639T3 (en)
ES (1) ES2734130T3 (en)
WO (1) WO2014026905A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9804161B1 (en) * 2012-05-14 2017-10-31 Lawrence Livermore National Security, Llc Detector and related, devices, methods and systems
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160334412A1 (en) * 2013-12-20 2016-11-17 Phadia Ab Analysis of antibodies
JP2019523404A (en) * 2016-07-15 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Method and means for detecting the level of total VEGF-A
CN109991405B (en) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 Immunoassay kit and application thereof
CN108623684B (en) * 2018-08-30 2018-12-18 宝船生物医药科技(上海)有限公司 A kind of monoclonal antibody and its application identifying Avastin
KR102612555B1 (en) 2020-12-18 2023-12-11 한국세라믹기술원 Immunoprecipitation using antibody binding protein-calsequestrin fusion protein

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177921A (en) * 1982-04-09 1983-10-18 Fujirebio Inc Anti-immune complex antibody and preparation thereof
US4757024A (en) * 1985-05-31 1988-07-12 Biostar Medical Products, Inc. Immune complex detection method and article using immunologically non-specific immunoglobulins
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
AU5611394A (en) * 1992-11-19 1994-06-08 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
US6991907B1 (en) * 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6194220B1 (en) 1996-09-25 2001-02-27 Becton, Dickinson And Company Non-instrumented assay with quantitative and qualitative results
US5998221A (en) 1996-09-25 1999-12-07 Becton, Dickinson And Company Non-instrumented assay with quantitative and qualitative results
US5798273A (en) 1996-09-25 1998-08-25 Becton Dickinson And Company Direct read lateral flow assay for small analytes
JP2000055917A (en) 1998-08-05 2000-02-25 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Method for detection or measurement using antigen- antibody complex antibody
ATE417925T1 (en) 1999-07-20 2009-01-15 Morphosys Ag METHOD FOR PRESENTATION OF (POLY)PEPTIDES/PROTEINS ON BACTERIOPHAGE PARTICLES VIA DISULFIDE BINDINGS
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
ATE503187T1 (en) 2004-12-23 2011-04-15 Hoffmann La Roche DETECTION OF A THERAPEUTIC ANTIBODIES IN A TESTIMONIAL ANIMAL
DK1888643T3 (en) * 2005-05-18 2015-01-05 Morphosys Ag Anti-GM-CSF antibodies as well as their uses
JP5759722B2 (en) * 2007-08-28 2015-08-05 アッヴィ バイオテクノロジー リミテッド Compositions and methods comprising adalimumab binding protein
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
FR2939431B1 (en) * 2008-12-05 2011-01-28 Valagro Carbone Renouvelable PROCESS FOR PRODUCING AN INTERMEDIATE PRODUCT FOR THE PRODUCTION OF ETHANOL AND INTERMEDIATE PRODUCT OBTAINED
CA2739310C (en) * 2009-07-21 2014-07-08 Sekisui Medical Co., Ltd. Insulin assay

Also Published As

Publication number Publication date
ES2734130T3 (en) 2019-12-04
CN104995517B (en) 2018-07-17
CA2878814A1 (en) 2014-02-20
KR102410763B1 (en) 2022-06-20
AU2013304237A1 (en) 2015-01-29
JP2015531762A (en) 2015-11-05
JP6437913B2 (en) 2018-12-12
EP2885639A1 (en) 2015-06-24
US20200339703A1 (en) 2020-10-29
CA2878814C (en) 2023-03-14
AU2013304237B2 (en) 2017-12-21
US20150197579A1 (en) 2015-07-16
KR20150041801A (en) 2015-04-17
EP2885639B1 (en) 2019-04-10
US10774154B2 (en) 2020-09-15
WO2014026905A1 (en) 2014-02-20
US20180134807A1 (en) 2018-05-17
US20240067753A1 (en) 2024-02-29
EP3540438A1 (en) 2019-09-18
CN104995517A (en) 2015-10-21

Similar Documents

Publication Publication Date Title
DK2885639T3 (en) COMPLEX SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND THEIR APPLICATION
IL290972A (en) Anti-vista antibodies and fragments
DK2914291T3 (en) ANTI-COMPLEMENT-C1S ANTIBODIES AND USES THEREOF
DK2794654T3 (en) ANTI-PHF-TAU ANTIBODIES AND THEIR USES
DK2785375T3 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
CO7071096A2 (en) Anti-lgr5 and immunoconjugate antibodies
DK2970460T3 (en) Anti-IL-33 Antibodies and Uses thereof
BR112015002193A2 (en) anti-etbr and immunoconjugate antibodies
BR112014012137A2 (en) anti-fgfr2 antibodies and their uses
DK3381943T3 (en) ANTI-KIT ANTIBODIES AND USES THEREOF
DK2850103T3 (en) ST2 antigen binding proteins
DK2776466T3 (en) Albumin-binding antibodies and binding fragments thereof
DK2812443T3 (en) CD47 ANTIBODIES AND PROCEDURES FOR USE THEREOF
DK3199552T3 (en) ANTI-CEACAM5 ANTIBODIES AND APPLICATIONS THEREOF
DK3333188T3 (en) Anti-NGF antibodies and their use
DK3026062T3 (en) ANTI-PD-1 ANTIBODY AND ITS USE
DK3027209T3 (en) Anti-Activin A Antibodies and Uses thereof
DK2934584T3 (en) ANTI-GDF15 ANTIBODIES
DK3556774T3 (en) Anti-CD40 antibodies and uses thereof
DK2850101T3 (en) Anti-FcRn antibodies
DK3339323T3 (en) ANTI-N3PGLU-AMYLOID-BETA-PEPTIDE ANTIBODIES AND APPLICATIONS THEREOF
BR112015003838A2 (en) antibody and protein formulations
DK2844286T3 (en) Lyophilized and aqueous anti-CD40 antibody formulations
DK2624866T3 (en) TUMOR-SPECIFIC ANTIBODIES AND USES THEREOF
DK3079719T3 (en) ANTI-SIGLEC-8 antibodies and methods for their use